Related references
Note: Only part of the references are listed.Effect of Sacubitril/Valsartan Combined with Dapagliflozin on Long-Term Cardiac Mortality in Heart Failure with Reduced Ejection Fraction
Umut Karabulut et al.
ANGIOLOGY (2022)
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC
Theresa A. McDonagh et al.
EUROPEAN JOURNAL OF HEART FAILURE (2022)
The Efficacy and Safety of Sacubitril/Valsartan in Heart Failure Patients: A Review
Rui Zhang et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2022)
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Paul A. Heidenreich et al.
JOURNAL OF CARDIAC FAILURE (2022)
Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial
Jawad H. Butt et al.
CIRCULATION (2022)
Evaluating Sacubitril/Valsartan Dose Dependence on Clinical Outcomes in Patients With Heart Failure With Reduced Ejection Fraction
Kazuhiko Kido et al.
ANNALS OF PHARMACOTHERAPY (2021)
Novel doses of sacubitril/valsartan in patients unable to tolerate traditional therapy: Effects on N-terminal pro B-type natriuretic peptide levels
Amitabh C. Pandey et al.
CLINICAL CARDIOLOGY (2021)
Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction
Hyue Mee Kim et al.
SCIENTIFIC REPORTS (2021)
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh et al.
EUROPEAN HEART JOURNAL (2021)
Impact of Sacubitril/Valsartan on Clinical and Echocardiographic Parameters in Heart Failure Patients With Reduced Ejection Fraction: Data From a Real Life 2-year Follow-Up Study
Giuseppe Armentaro et al.
FRONTIERS IN PHARMACOLOGY (2021)
Sacubitril/valsartan improves cardiac function in Chinese patients with heart failure: a real-world study
Wenwen Chen et al.
ESC HEART FAILURE (2021)
Angiotensin receptor neprilysin inhibitor for patients with heart failure and reduced ejection fraction: Real-world experience from Turkey (ARNi-TR)
Berkay Ekici et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2021)
Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure
Scott D. Solomon et al.
CIRCULATION (2020)
Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients
In-Chang Hwang et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Long-term LVEF trajectories in patients with type 2 diabetes and heart failure: diabetic cardiomyopathy may underlie functional decline
Maria Teresa Julian et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan The DAPA-HF Trial
Scott D. Solomon et al.
JACC-HEART FAILURE (2020)
Beneficial Effects of Sacubitril/Valsartan at Low Doses in an Asian Real-World Heart Failure Population
Jingwen Hu et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2020)
In HFREF patients, sacubitril/valsartan, given at relatively low doses, does not lead to increased mortality or hospitalization A retrospective cohort study
R. De Vecchis et al.
HERZ (2019)
Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study
Rolf Wachter et al.
EUROPEAN JOURNAL OF HEART FAILURE (2019)
Outcomes and Effect of Treatment According to Etiology in HFrEF An Analysis of PARADIGM-HF
Craig Balmforth et al.
JACC-HEART FAILURE (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Practical guidance on the use of sacubitril/valsartan for heart failure
Andrew J. Sauer et al.
HEART FAILURE REVIEWS (2019)
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure
Eric J. Velazquez et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Duration of chronic heart failure affects outcomes with preserved effects of heart rate reduction with ivabradine: findings from SHIFT
Michael Boehm et al.
EUROPEAN JOURNAL OF HEART FAILURE (2018)
Eligibility of sacubitril-valsartan in a real-world heart failure population: a community-based single-centre study
Helena Norberg et al.
ESC HEART FAILURE (2018)
Long-term neprilysin inhibition - implications for ARNIs
Duncan J. Campbell
NATURE REVIEWS CARDIOLOGY (2017)
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF
Michael Bohm et al.
EUROPEAN HEART JOURNAL (2017)
Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association
Biykem Bozkurt et al.
CIRCULATION (2016)
The war against heart failure: the Lancet lecture
Eugene Braunwald
LANCET (2015)
Impact of Diabetes on Epidemiology, Treatment, and Outcomes of Patients With Heart Failure
Alessandra Dei Cas et al.
JACC-HEART FAILURE (2015)
Heart failure in the diabetic population - pathophysiology, diagnosis and management
Jacek Kasznicki et al.
ARCHIVES OF MEDICAL SCIENCE (2014)
The Global Health and Economic Burden of Hospitalizations for Heart Failure Lessons Learned From Hospitalized Heart Failure Registries
Andrew P. Ambrosy et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure
John J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Heart failure: preventing disease and death worldwide
Piotr Ponikowski et al.
ESC HEART FAILURE (2014)
Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure
Scott D. Solomon et al.
CIRCULATION (2007)
Elevated plasma levels of Nt-proBNP in patients with type 2 diabetes without cardiovascular disease
M Magnusson et al.
DIABETES CARE (2004)
Share Paper
